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The extracellular matrix protein tenascin C (TnC) is expressed in a variety of embryonic tissues but 
its expression in adult arteries is co-incident with sites of vascular disease. TnC expression has been 
linked to the development and complications of intimal hyperplasia, pulmonary artery hypertension, 
atherosclerosis, myocardial infarction and heart failure. This review identifies the growing 
collection of evidence linking TnC with cardiovascular disease development. The transient 
upregulation of this extracellular matrix protein at sites of vascular disease could provide a means to 
target TnC in the development of diagnostics and new therapies. Studies in TnC deficient mice have 
implicated this protein in the development of intimal hyperplasia. Further animal and human studies 
are required to thoroughly assess the role of TnC in some of the other pathologies it has been linked 
with, such as atherosclerosis and pulmonary hypertension. Large population studies are also 
warranted to clarify the diagnostic value of this extracellular matrix protein in cardiovascular 
disease, for example by targeting its expression using radiolabelled antibodies or measuring 
circulating concentrations of TnC. 
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Tenascin C (TnC) is a large extracellular matrix glycoprotein and was the first member identified of 
a family of 4 structurally similar proteins including tenascin R, W and X 1-3. During early 
development TnC is transiently expressed at a number of sites throughout the embryo, such as 
neural crest, central nervous system, lungs and cardiovascular system 1. Despite this implied 
function during embryogenesis, knock out mice models of TnC grow to maturity without any overt 
signs of abnormalities 4. In normal adult tissue only low levels of TnC are found. Higher levels of 
TnC expression have been reported in areas of wound healing, cancer development and 
cardiovascular disease 1. Given this localisation of TnC to sites of pathology, there has been 
increasing interest in assessing the role of this glycoprotein in disease development and targeting 
the protein in both diagnosis and therapy for a variety of pathologies 1. In this review we summarise 
previous studies which have examined the expression and potential influence of TnC in 
cardiovascular disease.  
 
Structure of TnC 
The structure of tenascin C is relevant to its functions in health and disease and has been described 
in detail in previous reviews 1-3. TnC polypeptides are made up of a number of domains (Figure 1a) 
and include: 
a) An amino-terminal Tn assembly domain (TA) which is responsible for interactions between TnC 
polypeptides important in assembly of the multimeric protein; 
b) A contiguous group of repeats of epidermal growth factor-like domains; 
c) A series of fibronectin type III domains; 
d) A distal globular fibrinogen-homology domain.  
While TnC is encoded by a single gene located at 9q33 in man, alternative splicing of mRNA can 
result in a large number of different isoforms with between 1 and 6 extra fibronectin type III 
domains (A1, A2, A4, B, C and D) (Figure 1b). Ultimately six TnC polypeptides can be assembled 
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into a six armed structure referred to as a hexabrachion via interaction at the TA domains. This form 
of TnC has been identified within the extracellular matrix such as that present during embryonic 
development. The relative expression of different forms of TnC present in diseased adult tissue and 
circulating in the blood has been poorly described. 
 
TnC interactions and signalling pathways 
Associated with its complex structure TnC has the capacity to interact with several different cell 
surface receptors. Different parts of the TnC protein have been ascribed to binding different 
receptors 1,3. The epidermal growth factor-like domains can bind the epidermal growth factor 
receptor. The third fibronectin type III repeat binds αvβ3 and other integrins promoting adhesion. 
The variable spliced A-D fibronectin type III repeats bind annexin II thereby inhibiting adhesion. 
The variable splice region has also been shown to interact with F3/contactin and α7β1 integrin 3. 
Thus different isoforms of TnC would be expected to have different functional effects although this 
has not been clearly defined. 
 
In vitro studies assessing the determinants of TnC production and the interaction of TnC with 
vascular cells 
The determinants of TnC expression have been examined in vitro in a variety of cells relevant to 
vascular disease, including vascular smooth muscle cells (VSMCs), endothelial cells and monocyte-
macrophages (Table 1) 11-32. Overall, a range of factors implicated in cardiovascular disease, 
including cytokines, angiotensin II and haemodynamic forces appear to be able to upregulate TnC 
expression in vitro. A number of medications have been reported to reduce TnC expression 
including steroids, cilostazol and non steroidal anti-inflammatory drugs 18,21,30. Identified intra-
cellular regulators of TnC expression in vascular cells include homeobox transcription factor Prx1, 
Rho and extracellular signal-regulated kinases 17,24-26. TnC expression has been shown to be under 
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post-transcription control in non-vascular sites, such as within breast cancer metastases, where 
micro RNAs, including miR-355, have been shown to control TnC expression 33.   
 
The actions of TnC have also been examined in vitro employing a range of cell types and TnC 
fragments (Table 2) 16,26,27,34-56. TnC has been reported to promote angiogenesis and release of pro-
inflammatory cytokines and MMPs. TnC has also been reported to inhibit T cell proliferation and 
activation in vitro. The effects of TnC within in vitro studies seem to vary according to the fragment 
of TnC employed and the cell type studied. The region of TnC which contains the fibronectin type 
III repeats, and which varies by isoform type (Figure 1), appears to control the ability of TnC to 
influence cell adhesion 27,46,48,52,53. The epidermal growth factor-like domains of TnC have been 
suggested to control cell survival, while the distal globular fibrinogen-homology domain has been 
associated with stimulating cytokine production 8,37. 
 
Animal studies examining the expression and role of TnC in cardiovascular disease 
The association of TnC with a range of cardiovascular pathologies has been examined in murine, 
lapine, porcine, bovine and canine models of human cardiovascular diseases (Tables 3-5) 
11,16,21,23,27,29,39,40,57-76
. The most common pathology studied has been intimal hyperplasia (Table 3) 
11,21,29,39,57-63.
 TnC has been implicated in the development of intimal hyperplasia following 
angioplasty, stenting, arteriotomy and bypass grafting in animal species as diverse as mice and pigs 
11,21,29,39,57-63
. TnC is expressed very rapidly following arterial injury in these models and its 
expression is reduced in situations where intimal hyperplasia is inhibited such as prostaglandin E2 
deficiency or treatment with a nitric oxide donor 11,63. Importantly, intimal hyperplasia has been 
reported to be reduced in two distinct mouse models of TnC deficiency suggesting that this protein 
plays an active role in this pathology 57,58. Indeed in one study that employed arterial grafts placed 
in the carotid artery, a reduced proliferation of neointimal cells was demonstrated in TnC deficient 
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by comparison to wild type mice 57. This same research group reported a similar finding of reduced 
number and proliferation of neointimal cells after aortotomy in TnC deficient mice 58. 
 
Studies in rodent, pig and dog models of myocardial infarction have demonstrated that TnC is 
highly expressed from approximately day 1 to day 14 within the peri-infarct area. This has 
promoted interest in developing diagnostic aids that incorporate antibodies targeting this protein 
(Table 4) 40,64-69. The TnC expression has been linked to an exaggerated repair process after 
myocardial infarction with reduced interstitial fibrosis reported in TnC deficient mice following 
coronary artery ligation 64. TnC deficient mice also have reduced myocardial stiffness on 
echocardiography after myocardial infarction 64. TnC expression has also been positively linked to a 
range of other cardiovascular pathologies, including atherosclerosis; pulmonary artery hypertension; 
neovascularisation; the peri-infarct repair process following stroke; angiotensin II induced cardiac 
fibrosis; vasospasm following subarachnoid hemorrhage and vascular calcification (Table 5). 
16,23,27,29,64,70-76
. In keeping with in vitro findings noted earlier, neovascularisation has been reported 
to be reduced in TnC deficient mice, suggesting TnC promotes angiogenesis 16.  
 
To summarise, studies in animal models most clearly support a role of TnC in intimal hyperplasia 
although the exact mechanisms for this are unclear. Although TnC is associated with many other 
cardiovascular pathologies in animal models clear evidence that links TnC with their development 
and outcomes is currently lacking. 
 
Human studies examining the expression of TnC in relation to cardiovascular disease 
A large number of studies have examined the expression of TnC in biopsies removed from patients 
with a variety of cardiac and other cardiovascular diseases (Tables 6 and 7)  
 
15,16,26,37,40,44,77-89
. TnC expression within athero-thrombosis has been associated with acute 
coronary syndrome 16,44,77. TnC staining was localised in areas of plaque rupture and macrophage 
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infiltration. Similar to animal studies, TnC expression has also been localised within areas of 
intimal hyperplasia (at sites of coronary restenosis or in saphenous vein coronary artery bypass 
grafts); myocardial infarction; cardiomyopathy; and coronary valve calcification 40,44,78-81. High 
tissue levels of TnC have also been reported within a range of other cardiovascular pathologies 
including carotid atherosclerosis, pulmonary artery hypertension, abdominal aortic aneurysm, renal 
access graft intimal hyperplasia, renal transplant vasculopathy and varicose veins 15,26,37,82-89. In 
contrast to the large number of studies examining the expression of TnC in tissue biopsies, there 
have been fewer investigations of the association of circulating concentrations of TnC with 
cardiovascular disease 75,90-96. The serum or plasma concentration of TnC has been reported to be 
increased in patients with a range of cardiac problems, including acute myocardial infarction, 
pulmonary thromboembolism, pulmonary artery hypertension, left ventricular hypertrophy and 
dilated cardiomyopathy compared to controls in cross-sectional studies (Table 8) 90-96. Overall, the 
number of subjects included in these studies has been small however with a total of only 408 cases 
and 136 controls included in the independent cross-sectional studies identified in this systematic 
review (Table 8). The TnC isoform measured in these studies has varied but in most instances 
appears to have been the high molecular weight isoform containing the fibronectin type III C 
domain. Assays have been performed using commercial enzyme linked immunoassays from two 
different companies 92-94. The circulating TnC concentration has not only been reported to be 
increased in patients with cardiac disease but also related to specific clinical findings, imaging 
results and subsequent outcomes in these patients 92-98. Serum TnC concentration has, for example, 
been correlated with New York Heart Association functional class and left ventricular ejection 
fraction in patients with heart failure 93,95. Serum TnC has also been reported to predict the 
prospective incidence of cardiovascular events in patients who have recently had a myocardial 
infarction, have heart failure or chronic kidney disease 94,97,98. The reported area under the curves of 
receiver operator characteristic (ROC) curves in these studies were between 0.77 and 0.79 94, 98. 
These findings suggest that most likely serum TnC would need to be combined with other clinical 
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and biomarker predictors to be of clinical value. In summary data from human association studies 
fit with animal data linking TnC with a range of cardiovascular diseases although the therapeutic 
and diagnostic value of these associations has little examined.  
 
Association of genetic polymorphisms in the gene encoding TnC and cardiovascular disease 
TnC is encoded by a large gene composed of 28 exons spanning nearly 100kB on Chromosome 9 
(NCBI Nucleotide database Ref Seq NC_000009). Its transcription is directed by a single promoter 
and regulated by both positive and negative elements located in the first untranslated exon 99, which 
is separated from the translation initiation site in exon 2 by a large intron of approximately 18kb 100. 
There are 1167 polymorphisms located in and around the gene, 67 of which affect the coding region 
(NCBI dbSNP), however, their functional consequences and association with cardiovascular disease 
has not been thoroughly investigated. It is tempting to speculate that inheritance of particular 
polymorphic variants could influence expression levels of TnC and account for some of the 
individual variation in risk of cardiovascular disease. A genome-wide association study of genes for 
biomarkers of cardiovascular disease identified rs17819305, located in intron 15 of the TnC gene, 
as being associated with gammaglutamyl transferase levels in 1955 hypertensive subjects 101. 
Otherwise, there has only been a single published study specifically examining the association of 
genetic polymorphisms in TNC and cardiovascular disease, and this did not include rs17819305 102. 
Minear and colleagues genotyped a total of 35 single nucleotide polymorphisms (SNPs), including 
21 haplotype tagging SNPs, in a range of subjects that had been assessed for different measures of 
atherosclerosis. The subjects examined included 205 heart transplant donors who had provided 
ascending aortic samples; 1325 patients who had undergone coronary angiography to assess 
severity of coronary atherosclerosis; and 879 families with a history of coronary heart disease. 
Three SNPs, rs3789875, rs12347433 and rs4552883, representing a block of linkage disequilibrium 
were significantly associated with aortic atherosclerosis plaque presence in the heart transplant 
donors and coronary heart disease in the two large subject groups. One of these SNPs, rs12347433, 
 at Jam



















is a synonymous polymorphism causing a change in the mRNA without affecting the amino acid 
sequence of the TnC protein. This type of synonymous polymorphism has been suggested to alter 
mRNA function or stability which could alter translation and thus TnC expression. However, none 
of these SNPs were associated with TnC expression measured by microarrays within the 104 
patients in which aortic RNA was available, suggesting these polymorphisms may be acting via 
mechanisms unrelated to aortic concentration of TnC mRNA.  
 
Summary and future directions 
A large number of studies suggest that TnC is transiently expressed in association with a range of 
cardiovascular diseases in both animal models and patients. Whether this association is part of the 
repair process or pathological is not completely resolved in most instances. Studies from TnC 
deficient mice suggest that in the case of intimal hyperplasia (perhaps the best studied example) that 
TnC plays a pathological role, most likely because of the ability of TnC to promote MMP 
production, and VSMC proliferation and chemotaxis 26,40,43,50,57,58. The role of TnC in 
atherosclerosis is less clear cut although a number of findings (such as its expression at sites of 
plaque rupture, its involvement in neovascularisation and its ability to influence VSMC phenotype 
and pro-inflammatory cytokine/ MMP production) would suggest it may play a role in promoting 
the development and complications of this pathology 8,16,42,44,51,77. We identified no studies 
examining TnC deficiency, overexpression or inhibition on atherosclerosis progression in animal 
models. Studies of this type are required to provide further insight on the role of this extracellular 
matrix protein in cardiovascular disease. The rapid upregulation of TnC following ischemia events, 
such as myocardial infarction, suggests the possibility of targeting TnC as a diagnostic or 
prognostic aid in patients with cardiovascular disease, e.g. as a circulating or tissue biomarker 81,94. 
Further studies in larger populations are however required to assess the feasibility and clinical value 
of such an approach. 
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Legend to the figure 
Figure 1: Structure of Tenascin C.  
(a) This diagram has been adapted from previous work using predicted domain boundaries to 
determine the overall structure of the protein. A recent study suggested the earlier delineations 
derived from reverse transcription polymerase chain reaction and Western blotting ((b) shown 
below the main structure) had several flaws and did not correlate to the natural domain boundaries 
particularly in the A1-4 region 5. The N-terminal domain is called the tenascin assembly domain 
(TA) and is involved in the formation of the quarternary hexabrachion structure. Within this region 
there is a heat shock protein 33 motif probably responsible for TnC aggregation within the cell 5. 
The next region includes 14 epidermal growth factor (EGF) like repeats which are quite consistent. 
The EGF-like repeat domain modulates cell adhesion and cell motility 6. This region is considered 
to be counter adhesive for fibroblasts, neurons and glia and may be involved in neuronal migration 
and axon path finding during development 1. The following region contains the fibronectin (FN) III 
like repeats. The FN-III repeats vary considerably in amino acid sequence and have a variety of 
ligands 7. The final C-terminal domain is the fibrinogen (FG)-like domain. This domain is the 
region of the protein that binds to toll-like receptor (TLR)-4 as an endogenous ligand 8. Due to 
alternative splicing of pre mRNA of the FN III-like repeats, 6-12, TnC exists as a number of 
isoforms with varying functions and sizes. The smallest isoform has a predicted molecular weight 
of 171.3 kDa and is missing repeats 6-12. The largest isoform with a predicted molecular mass of 
240.8 kDa has all the FN III-like repeats included 9. TnC is also glycosylated 10 giving rise to the 
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Table 1: Determinants of TnC expression in vitro in a variety of cells relevant to 
cardiovascular disease 
Upregulators of TnC Cell type studied TnC form induced 
Prostaglandin E2 Mouse VSMCs 11 mRNA 
LPS and other TLR ligands Monocyte derived cells such as 
macrophages 12 
mRNA and protein 
Wnt pathway Mouse pulmonary artery 
VSMCs 13 
mRNA and protein 
CD137 ligation RAW264.7 (murine myeloid 
cell line) 14 
mRNA 
ERK 1/2 mitogen-activated 
protein kinases 
Human pulmonary artery 
VSMCs 15 
mRNA and protein 
RhoA and Rho kinase ROCK Rat pulmonary artery 
endothelial cells 16,17 
mRNA 
Interleukin-4 Human peripheral blood 
derived macrophages 18 
mRNA 
Cyclic stretch Human aortic VSMCs 
Rat aortic VSMCs 19,20 
mRNA and protein 
Platelet derived growth factor Rat aortic VSMC 21-23 mRNA and protein including 
three isoforms (210, 220 and 
250 kDa) 
Prx1 (homeobox transcription 
factor) 
VSMC cell line 24 mRNA 
Denatured collagen (via β3 
integrin and ERK 1/2) 
VSMC cell line 25,26 mRNA and protein 
Angiotensin II Human aortic VSMC mRNA and protein 
 at Jam



















Rat aortic VSMC 
Human aortic endothelial cells 
22,23,27,28 
Transforming growth factor 
beta 
Human aortic VSMC 
Rat aortic VSMC 
Human aortic endothelial cells 
 
23,27 
mRNA and protein 
Downregulators of TnC Cell type studied TnC form downregulated 
Shear stress mimicking 
atheroprone flow 
Human iliac vein endothelial 
and VSMC co-culture 29 
mRNA 
Dexamethasone  Human peripheral blood 
derived macrophages 18 
mRNA 
Cilostazol Rat aortic VSMC 21 mRNA 
Glafenine hydrochloride 
(NSAID) 
Human aortic VSMCs 30 Protein 
9-cis retinoid acid Human aortic VSMCs 31 Protein 
Polymerised (compared to 
monomer) type 1 collagen 





TnC, Tenascin C; LPS, Lipopolysaccharide; TLR, Toll-like receptor; Wnt, Wingless; VSMC, 
Vascular smooth muscle cell; NSAID, Non-steroidal anti-inflammatory drugs. 
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Table 2: Reports of the effects of TnC on cells relevant to cardiovascular disease in vitro 
TnC form or intervention Cell type Effects 
TnC fragment (A2 isoform) Human dermal microvascular 
endothelial cells 
Proliferation inhibited 36 
TnC from commercial 
company (Chemicon) 
Rat cardiac microvascular 
endothelial cells 
Promotes response to 
angiogenic signals such as 
PDGF and VEGF 16  
TnC from commercial 
company (Chemicon) 
Bovine and human retinal 
endothelial cells 
Promotes endothelial cell 
tube formation and branching 
38
 
Recombinant chick TnC  Bovine aortic endothelial 
cells 
Stimulates actin cytoskeletal 
reorganisation typical of 
sprouting endothelial cells 45 
Large and small splice 
variants of TnC 
Bovine aortic endothelial 
cells 
TnC fragment containing Fn 
A-D induces loss of focal 
adhesion by binding annexin 
II 52,53 
TnC blocking antibody Bovine aortic endothelial 
cells 
Inhibits signs of angiogenesis 
such as sprouting cells 54 
TnC from a cell line Human umbilical endothelial 
cells 
Binds to α2β1 and αvβ3 
integrins 55 
Large isoform of TnC Rat and Human VSMC Upregulates MMP-2 which 
cleaves TnC 37 
EGF-like TnC domain Rat and Human VSMC Induces apoptosis 37 
Recombinant A1A2 isoform Rat VSMC Promotes VSMC chemotaxis 
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(unlike other TnC isoforms) 
39
 
TnC isolated from a glioma 
cell line 
Adult rat cardiomyocytes Promotes cardiomyocyte 
attachment to laminin 40 
TnC antisense 
oligonucleotide 
Rat pulmonary arteries in 
organ culture 
Promotes VSMC apoptosis 
and upregulates osteopontin 
expression 43 
Human TnC from 
commercial company 
(Chemicon) 
Rat pulmonary artery 
VSMCs 
Stimulates proliferation and 
survival via αVβ3 integrin 
26,50
 
TnC fragment containing Fn 
A-D 
Human aortic VSMC 
Human aortic endothelial 
cells 
Reduces focal adhesion 
VSMC> endothelial cells 27 
 
TnC deficient mouse Mouse macrophages Behaved as wild type 
macrophages in response to 
TGFβ1 34 
Human recombinant TnC 
(fibrinogen-like globe) 
Human macrophages Stimulated TNFα, IL-6 and 
IL-8 production 8 
TnC extracted from chick 
embryo brains 
Human polymorphonuclear 
leukocytes and monocytes 
Inhibited chemotaxis via 
α5β1 integrin 42 




Stimulates MMP-9 secretion 
44
 
TnC from commercial 
company (Life Technologies) 




TnC from chick embryo 
fibroblast cultures  
Human monocytes and T 
lymphocytes 
Inhibited monocyte adhesion 
to fibronectin and T cell 
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  activation by alloantigens not 
anti-CD3 antibody 56 
TnC isolated from U251 
glioma cell line and 
recombinant fragments  
Human T lymphocytes TnFnIII A1A2 inhibits T cell 
activation 41 
Recombinant TnC fragments 
 
Human T lymphocytes TnfnIII 1-5 inhibits αVβ1 
and α4β1 mediated adhesion 
to fibronectin 46 
TnC isolated from U251 
glioma cell line (Chemicon) 
Human T lymphocytes Inhibited anti CD3 induced 
cell proliferation 47 
Recombinant TnC fragments 
 
Human T lymphocytes Supports tethering and 
rolling via binding to the 
terminal fibrinogen like 
domain of TnC in a parallel-
plate flow chamber 48 
Plasmin cleaved TnC Human T lymphocytes Plasmin cleavage of TnC 
converts it from a 
nonadhesive to an adhesive 
substrate for T cells 49 
TnC isolated from U251 
glioma cell line 
Human platelets Platelets adhere to and are 
activated by TnC 35 
 
TnC, Tenascin C; PDGF, Platelet derived growth factor; VEGF, Vascular endothelial growth factor; 
MMP, matrix metalloproteinase; TGF, Transforming growth factor; TNF, Tumour necrosis factor; 
IL, Interleukin; TnfnIII, Tenascin C fibronectin type III repeat domain; VSMC, Vascular smooth 
muscle cells. 
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Table 3: Association of TnC expression with intimal hyperplasia in animal models 
Intimal hyperplasia model and species Findings at site of intimal hyperplasia 
Wire femoral artery injury; mouse Reduced intimal hyperplasia in PGE2 deficient mouse 
associated with reduced TnC mRNA expression 11 
Abdominal aorta-to-carotid artery 
interposition grafting; mouse 
Reduced neointimal hyperplasia in TnC deficient 
mice 57 
Longitudinal aortotomy; mouse TnC deficient mice have reduced intimal hyperplasia 
58
 
Balloon aortic injury; rat Increased TnC protein expression first within the 
media and later the neointima 29 
Arterial graft; rat Topical cilostazol inhibits intimal hyperplasia 
associated with decreased TnC protein expression 21 
Balloon carotid injury; rat Increased AIA2 TnC isoform mRNA and protein 
expression associated with intimal hyperplasia 39 
Balloon carotid injury; rat TnC protein expression increased within the intima 
after balloon injury 59 
Balloon carotid injury; rat and pig Increased TnC mRNA and protein expression in 
adventitial myofibroblasts early and intima late after 
injury 60 
Left coronary artery stenting; miniature pig TnC mRNA and protein expression associated with 
the severity of intimal hyperplasia 61 
Coronary artery angioplasty; pig Upregulation of TnC mRNA within 2 h of injury 62 
Jugular vein grafts implanted in carotid 
artery; hypercholesterolemic rabbit 
Topical nitric oxide donor reduces intimal hyperplasia 
and TnC protein expression within graft 63 
 
TnC, Tenascin C; PGE2, Prostaglandin E2. 
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Table 4: Association of TnC expression with post myocardial infarction changes in animal 
models 
Myocardial infarction 
model and species 
Findings 
Coronary artery ligation; 
mouse 
TnC deficient mice had less interstitial fibrosis in peri-infarct areas 64 
Temporary left coronary 
occlusion; mouse 
Smad 3 deficient mice had reduced myocardial TnC protein expression 
post infarction 65 
Temporary left coronary 
occlusion; rat 
(125)I-labeled anti-TnC antibody uptake at 1-3 days after infarction; 
reduced by 7 days 66 
Left coronary ligation; 
rat 
111In anti-TnC antibody uptake increased day 1-5 following infarction 
67
 
Coronary artery ligation: 
rat 
TnC mRNA and protein expression in fibroblasts in the area of 
infarction within 24 hours which disappears by 14 days- involvement in 
the phases of MI healing 40 
Left anterior descending 
artery occlusion; pig 
Mesenchymal stem cell injection association with cardiac TnC protein 




Cardiac TnC protein upregulated 69 
 
TnC, Tenascin C; MI, Myocardial infarction. 
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Model and species Findings 
Atherosclerosis Apolipoprotein E deficient; 
mouse 
Increased TnC protein expression in areas of 
atheroma 29 
Atherosclerosis Apolipoprotein E deficient; 
mouse 
Increased TnC protein staining in areas of 
atheroma and activated macrophages 70 
Atherosclerosis Spontaneously 
hypertensive; rats 
Aortic TnC protein staining increased with 
age, hypertension, and at branch points 23,27 
Pulmonary artery 
hypertension 
Chronic hypoxia induced 
PAH; rat and calf 
Circulating monocyte/ macrophage 




PAH; rat  
Upregulation of pulmonary artery TnC 
protein associated with PAH; Endothelin B 




Pulmonary artery ligation; 
pig 
Increased pulmonary TnC mRNA and protein 
expression 73 
Neovascularisation Bone marrow transplant 
plus intramyocardial PDGF 
injection; mouse 
Donor derived cells recruited to the heart 
within 24h of PDGF injection at sites of TnC 
protein expression 16 
Neovascularisation Cardiac transplant; mouse TnC deficient mice reduced 
neovascularisation 16 
Cerebral infarction Middle cerebral artery 
occlusion; rat 
Genomic study of peri infarct cortex showed 
upregulation of TnC mRNA 74 
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Cardiac fibrosis Angiotensin II infusion; 
mouse 
Cardiac fibrosis associated with increased 
TnC mRNA and protein expression 64 
Sub-arachnoid 
hemorrhage 
Cisternal injection of 
blood; rat 
TnC protein staining increased at sites of 
artery vasospasm 75 
Vascular 
calcification 
Subdermal injection of 
elastin; rat 
Increased TnC protein staining along with 
MMPs at sites of calcification 76 
 
TnC, Tenascin C; PAH, Pulmonary artery hypertension; PDGF, Platelet derived growth factor; 













































None TnC expressed within 
coronary artery thrombus and 






Stable angina TnC staining area larger in 
atheroma from patients with 
ACS and correlated with 
thrombus, angiogenesis, 










from the same 
patients  
TnC staining in areas of 
plaque rupture and correlated 
with macrophage infiltration 
44
 






TnC expression increased in 
biopsies with more severe 
histological evidence of 
cardiac damage 78 
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PM cases with 
no history of 
cardiac disease 
Cardiomyopathy cases 
increased TnC expression 79 





PM cases with 
no history of 
cardiac disease 












TnC expression increases 
transiently within 1 month of 









TnC protein expressed within 
the adventitia and media of 
patent vein grafts but not 
within occluded vein grafts 
or non-arterialised control 







TnC expressed post MI up to 
3 weeks after 81 
 
EPC, endothelial progenitor cells; ACS, acute coronary syndrome; TnC, tenascin C; PM, post 
mortem; MI, myocardial infarction. 
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Table 7: Studies examining the expression of TnC in biopsies taken from patients with a 

















Staining for TnfnIII marked 
in atherosclerotic plaques 
and particularly macrophage 






None Large (280kD) and small 
(220kD) TnC isoforms and 
85 and 65kD EGF-like 




























None TnC highly expressed in all 
biopsies 15 
7 Pulmonary Pulmonary artery None TnC staining correlates with 
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Increased staining for TnC in 












NS Reduced TnC expression by 
VSMCs from aneurysm 
biopsies 87 
12 Graft stenoses Failed PTFE loop 
arterio-venous grafts 
None TnC staining marked in 
luminal layer of intimal 
hyperplasia at the site of cell 
proliferation based on 
proliferating cell nuclear 
antigen expression 88 
10 Renal arteries Failed kidney 
transplants 
None Increased TnC expression 
observed in media early in 
rejection process 89 
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EGF, Epidermal growth factor; TnC, Tenascin C; AAA, Abdominal aortic aneurysm; VSMC, 
Vascular smooth muscle cells; PTFE, Polytetraflurorethylene; NS, Not stated. 
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Table 8: Case-control studies examining the association of circulating TnC concentrations 
with cardiac disease 
Cases controls Sample Other findings 
Diagnosis N TnC 
(ng/ml) 







34 120±38* Healthy 
volunteers 
20 16±3 Plasma  
Pulmonary artery 
hypertension 91 


















Serum TnFNIIIB higher 







107 73±35* Healthy 
volunteers 






Acute myocardial 105 83±43* Healthy 20 27±12 Serum Peak TnC 
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infarction (day 5) 94 volunteers predicted 




















64 60±40 Patients 
responding 
to CRT  
46 47±30* Serum TnC dropped in 
72% of treated 
patients at 6 
month follow-up 
 
Comparisons of TnC between cases and controls: *p<0.01; **p<0.05. Shown are mean and 
standard deviation except † where median and inter-quartile range are shown. ‡In this study the 
lower molecular weight FNIIIB domain containing TnC isoform was measured while in other 
studies the higher molecular weight FNIIIC domain containing TnC isoform appears to have been 
measured. TnC, Tenascin C; AUC, Area under the curve; ROC, Receiver operator characteristic; 
LV, Left ventricular; NYHA, New York Heart Association; MACE, major adverse cardiovascular 
events; CRT, cardiac resynchronisation therapy. 
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